$324 Million is the total value of Tamarack Advisers, LP's 35 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 157.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | New | SPDR S&P 500 ETF Trust Oct3 370.0 Pput | $175,244,000 | – | 400,000 | +100.0% | 54.16% | – |
| TLT | New | iShares 20 Plus Year Treasury Bond ETF Sep3 110.0 Ccall | $15,441,000 | – | 150,000 | +100.0% | 4.77% | – |
| COLL | Buy | COLLEGIUM PHARMACEUTICAL ORDequity | $8,058,750 | -5.4% | 375,000 | +5.6% | 2.49% | -20.0% |
| BMRN | New | BIOMARIN PHARMACEUTICAL ORDequity | $6,501,000 | – | 75,000 | +100.0% | 2.01% | – |
| MCK | Buy | MCKESSON ORDequity | $5,982,340 | +460.1% | 14,000 | +366.7% | 1.85% | +374.1% |
| ABT | New | ABBOTT LABORATORIES ORDequity | $4,905,900 | – | 45,000 | +100.0% | 1.52% | – |
| ATRC | Buy | ATRICURE ORDequity | $4,195,600 | +150.7% | 85,000 | +110.5% | 1.30% | +111.9% |
| BDX | New | BECTON DICKINSON ORDequity | $3,960,150 | – | 15,000 | +100.0% | 1.22% | – |
| TEVA | New | TEVA PHARMA IND ADR REP 1 ORDequity | $3,388,500 | – | 450,000 | +100.0% | 1.05% | – |
| ALKS | Buy | ALKERMES ORDequity | $3,130,000 | +48.0% | 100,000 | +33.3% | 0.97% | +25.1% |
| IRWD | Buy | IRONWOOD PHARMA CL A ORDequity | $2,394,000 | +8.4% | 225,000 | +7.1% | 0.74% | -8.3% |
| DXCM | New | DEXCOM ORDequity | $2,056,160 | – | 16,000 | +100.0% | 0.64% | – |
| MDRX | New | Veradigm Inc Jul3 10.0 Ccall | $1,260,000 | – | 100,000 | +100.0% | 0.39% | – |
| SPB | New | SPECTRUM BRANDS HOLDINGS ORDequity | $780,500 | – | 10,000 | +100.0% | 0.24% | – |
| BIO | Buy | BIO RAD LABORATORIES CL A ORDequity | $758,240 | +58.3% | 2,000 | +100.0% | 0.23% | +33.7% |
| TECH | Buy | BIO TECHNE ORDequity | $326,520 | +340.1% | 4,000 | +300.0% | 0.10% | +274.1% |
| New | SOMALOGIC EQY WARRANTcall | $46,200 | – | 20,000 | +100.0% | 0.01% | – | |
| New | KENVUE ORDequity | $26,420 | – | 1,000 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERADIGM ORD | 32 | Q3 2023 | 13.9% |
| STREAMLINE HEALTH SOLUTIONS ORD | 30 | Q3 2023 | 4.0% |
| ATRICURE ORD | 29 | Q3 2023 | 7.6% |
| PACIRA PHARMACEUTICALS INC | 27 | Q1 2023 | 12.1% |
| LANTHEUS HOLDINGS ORD | 25 | Q4 2022 | 9.6% |
| MEDTRONIC PLC | 21 | Q1 2022 | 12.7% |
| RIGEL PHARMACEUTICALS ORD | 21 | Q2 2023 | 8.0% |
| BIO RAD LABORATORIES CL A ORD | 19 | Q2 2023 | 10.0% |
| HOLOGIC INC | 17 | Q1 2022 | 6.5% |
| SPY US 10/21/16 P210 | 17 | Q3 2023 | 41.5% |
View Tamarack Advisers, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTIONS INC. | June 22, 2023 | 5,514,515 | 9.4% |
| IVERIC bio, Inc. | February 16, 2021 | 850,000 | 0.1% |
| Correvio Pharma Corp. | February 14, 2020 | 2,500,000 | 4.9% |
| OBALON THERAPEUTICS INC | February 14, 2020 | ? | ? |
| Correvio Pharma Corp. | February 15, 2019 | ? | ? |
| Corium International, Inc. | February 15, 2017 | 737,242 | 3.3% |
| ENDOLOGIX INC /DE/Sold out | February 15, 2017 | 0 | 0.0% |
| Imprivata IncSold out | February 15, 2017 | 0 | 0.0% |
View Tamarack Advisers, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-16 |
| 13F-HR | 2023-08-10 |
| SC 13D/A | 2023-06-22 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-13 |
| SC 13D/A | 2022-12-01 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-11 |
View Tamarack Advisers, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.